Twist Bioscience Corporation
TWSTHealthcare|Biotechnology|US
$120.79
+0.18 (+0.15%)
Tangible Book / Share
$5.62
Cash / Share
$2.67
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT00313053 Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia | Leukemia, Lymphocytic, Acute, Leukemia | P1 | Terminated | 4 | Open-label | Human mAb 216, Vincristine |
| NCT02299960 Measurement of Endothelial Function and Cardiac Output: New Methods | Heart Failure, Hypertension, Pulmonary | Completed | 101 | — | — |